35.00NOK-2.78%Mkt Cap: 541.05M NOKP/E: —Last update: 2026-06-01
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemi…
Industry Peers
Medical Devices152.01BUSDP/E 24.4
115.59BUSDP/E 34.9
71.08BUSDP/E 20.0
54.41BSEKP/E 101.6
52.05BDKKP/E 22.0
51.03BUSDP/E 47.9
50.55BSEKP/E 21.4
38.34BEURP/E 18.1
Indicators:|
Key Statistics
Company
Market Cap541.05M NOK
Enterprise Value481.03M NOK
Revenue (TTM)175.92M NOK
Gross Profit98.20M NOK
Net Income (TTM)13.26M NOK
Revenue/Share11.41 NOK
Last Price35.00 NOK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees63
CountryNO
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)9.18
PEG—
EV/EBITDA24.64
EV/Revenue2.73
P/S3.16
P/B3.00
EPS (TTM)-0.96
EPS (Forward)3.92
52W Range
34.203% of range65.80
52W High65.80 NOK
52W Low34.20 NOK
Profitability
Gross Margin55.64%
Oper. Margin6.17%
EBITDA Margin11.10%
Profit Margin7.51%
ROE6.47%
ROA5.13%
Growth
Revenue Growth-1.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF42.59M NOK
CapEx (TTM)10.76M NOK
FCF Margin4.10%
FCF Yield1.33%
Net Debt-74.17M NOK
Net Debt/EBITDA-3.80
Balance Sheet
Debt/Equity0.11
Current Ratio5.70
Quick Ratio4.01
Book Value/Sh12.01 NOK
Cash/Share5.957 NOK
Dividends
Fwd Div Rate0.6000 NOK
Trail. Div Rate0.6000 NOK
Div. Yield1.69%
5Y Avg Yield—
Payout Ratio46.51%
Ex-Div DateMay 6, 2026
Pay Date—
Analyst Consensus
Rating—
Target (Mean)60.00 NOK
Target Range60.00 NOK – 60.00 NOK
# Analysts1
Ownership
Shares Out.15.46M
Float11.67M
Insiders44.62%
Institutions39.56%
Technical
SMA 5039.98 (-12.4%)
SMA 20050.18 (-30.3%)
Beta0.43
S&P 52W Chg27.70%
Avg Vol (30d)11.25K
Avg Vol (10d)9.01K
Technical Indicators
RSI (14)38.8
MACD-1.5337
MACD Signal-1.2044
MACD Hist.-0.3293
BB Upper44.49 NOK
BB Middle38.86 NOK
BB Lower33.24 NOK
BB Width28.93%
ATR (14)2.188 NOK
Vol Ratio (20d)1.30x